The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy

Drug Des Devel Ther. 2022 Apr 29:16:1255-1272. doi: 10.2147/DDDT.S355059. eCollection 2022.

Abstract

Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL.

Keywords: cancer therapy; cellular processes; nanomedicine; parthenolide; signaling pathways.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Neoplastic Stem Cells
  • Sesquiterpenes* / pharmacology
  • Sesquiterpenes* / therapeutic use

Substances

  • Antineoplastic Agents
  • Sesquiterpenes
  • parthenolide